The medical genetic testing, agricultural genetic testing and research genetic testing markets are clearly defined and will be subject to high rates of growth over the next decade. The medical genetic market was estimated to be $5.9 billion in 2011 and projected to exceed $20 billion by 2020. A major driver for this market is the adoption of NextGen Sequencing (NGS) in becoming standard for research and clinical use. Understanding the functions of variants in genes has become the next frontier. The flow variant analysis (FVA) technology that Morgan and Mendel offers provides this functional analysis that directly impact the use of NGS. FVA technology is applicable to the human, animal and plant health markets, both as adjuncts to NGS technologies and as direct tests to assess risks of disease, responses to therapy and development of toxicities.